



Background

Pyoderma gangrenosum (PG) is a non-healing, ulcerative skin disorder first described in 1930. It is a challenging disease to treat in terms of both diagnosis and treatment. However, familiarity with this disease may help increase the ability to treat patients.

Etiology

The etiology of PG is generally unknown. There is an association between PG lesions and demonstrated abnormalities in neutrophil function. Proposed theories include: Sublysis of adhesion proteins, resulting in abnormal migration of neutrophils; Intracellular metabolic mutations resulting in abnormal tracking of neutrophils; Drug-induced PG described, due to methyl, bromide, bromates, colony-stimulating factors, propylthiouracil, and alpha-2 agonists.

Characteristics and Clinical Appearance

Demonstrates pathergy phenomenon (lesion at site of injury). Typically begins as discrete pustule or pustule surrounded by erythema. May have been, perforating, nodular, and erythematous. Pustule breaks down into deep, red or purple ulcer. Center of ulcer is heaped up, and may be covered by hemorrhagic fibrin. Can be ulcer or may be ulcer on. 50-75% of cases associated with an underlying disease (See Table 1). Four types of PG lesions: Typical PG (most common) (red, purple, nodular, ulcer); Atypical or fulminant PG (found more commonly in patients with hematologic disease); Acute PG (found on back, palm, heel); Regional PG (found on hand or neck, may have hemorrhagic signs from ulceration).

Demographics

Most common in people aged 25-54. Occurs in men and women. Incidence difficult to determine, because of rarity of the disease.

Diagnosis

Rule by exclusion (See differential in Table 2). Allergy screen depending on type of PG, but most commonly shows negative results. Infection, hematologic, and organ disease. Biopsy usually results, unless secondary infection present.

Management

Systemic treatment for patient with PG with local systemic therapies, depending on extent of disease. Local therapy consists of injection into the lesion. Best outcome report used 1-trimethoprim-sulfamethoxazole. Other local treatments reported: heparin, sodium hyaluronate, topical 5-aminosalicylic acid, topical sodium cromoglycate, topical nitroglycerin ointment, and topical steroids on transformed pustules. Systemic therapy most commonly consists of prednisone therapy, 40-120 mg/day until ulcer is completely resolved, followed by tapering of therapy. A therapy has also been used. Other systemic treatments reported to be successful include cyclosporine, 200 mg/day, methotrexate, and plasmapheresis with cyclophosphamide. A relationship is controversial because of the pathergy nature.




Table 1

Diseases Associated with Pyoderma Gangrenosum

- A. Inflammatory bowel disease (eg, UC)
- B. Arthritis (psoriatic arthritis or psoriasis arthritis)
- C. Hematoma (eg, lung)
- D. Hematologic malignancy (leukemia, lymphoma, myelodysplasia, multiple myeloma)
- E. HIV
- F. Adrenocortical insufficiency
- G. Scurvy

Differential Diagnosis of PG-Like Lesions

- A. Infectious process
- B. Angioma
- C. Vasculitis
- D. Insect bite
- E. Toxic epidermal necrolysis
- F. Pyoderma
- G. Dermatitis associated with trauma
- H. Sweet's syndrome
- I. Pyoderma gangrenosum

Case

Chief Complaint

Patient is a previously healthy 22-year-old male presenting with a 2-month history of progressively spreading ulcer on his leg.

History of Present Illness

Two weeks prior to the onset of the ulcer, patient reported to fall after tripping on a small obstacle. He recalls no other trauma to his leg. The site of injury became tender and developed a painless ulcer. The ulcer continued to grow over several weeks to form a large, deep, yellow substance. Patient recalls no fever, malaise, myalgia, or arthralgia. Patient reports no other symptoms.

Physical Exam

Patient's vital signs were within normal limits, with temperature 37.2°C and heart rate 100 bpm. There was a 2 cm ulcer on the left leg with a central area of necrosis and a 5 cm area of erythema surrounding the ulcer.

Management

The patient had received several courses of antibiotics (vancomycin, ceftriaxone, rifampin, vancomycin, and rifampin) and intravenous immunoglobulin. The ulcer showed no improvement. In this case, a presumptive diagnosis of PG was made, which was confirmed through an outpatient dermatology consult. The patient was treated with 40 mg prednisone daily, and showed impressive improvement within 9 weeks. Physical therapy (physical therapy) was also used to aid in the healing of the ulcer and were able able to minimize the patient's pain. Initial pain medication was necessary. The patient was scheduled for a follow-up, but was subsequently lost to follow-up.

Conclusion

Our patient's diagnosis was made based on clinical presentation. There being no underlying disease, which did not meet a diagnosis for which we would expect to exclude other possibilities. Ideally, the patient would have undergone a laboratory because of the high incidence of IBD in patients with PG. In addition, histologic findings have been reported in the patient, the clinical picture may have been clearer.

Our case well illustrates the difficulty PG can present a disease. The long differential diagnosis for ulcer of this sort can lead to a long and expensive treatment which actually exacerbates the disease. Familiarity with PG is important because the clinical picture can be very confusing. With a sufficient grasp of the disease and its management, a physician will be well prepared to treat and manage this challenging disease.